Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients

Takeda Pharmaceutical Co Ltd TAK shared new analyses of Livtencity (maribavir), including additional analyses from Phase 3 SOLSTICE trial data, which supported the FDA approval of Livtencity.
Livtencity is approved in the U.S. for patients aged 12 years and above with post-transplant cytomegalovirus (CMV) infection/disease refractory to treatment.
Data from an exploratory analysis of the Phase 3 SOLSTICE trial showed that 31.9% of patients treated with Livtencity had at least one hospitalization compared to 36.8% of patients treated with conventional therapies.
Also Read: Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection.
The Livtencity treatment group had a 34.8% reduction over the conventional therapy group (p=0.021).
The length of hospital stay during the treatment phase was 13.27 days/person/year in Livtencity-treated patients compared to 28.73 for those conventionally treated, a 53.8% decrease (p=0.029).
Price Action: TAK shares are down 0.89% at $14.42 during the market session on the last check Friday.